Recurrence of Preinvasive Cervical Lesions After LEEP at Kilimanjaro Christian Medical Centre
Recurrence after loop electrosurgical excision procedure is a clinical signal that follow-up systems, pathology risk markers, and patient-level factors are as important as the excision itself. At Kilimanjaro Christian Medical Centre, where cervical cancer prevention services serve a large referral population in northern Tanzania, this issue carries added weight: many patients present with advanced risk profiles, and loss to follow-up can turn a treatable precursor lesion into invasive disease.
LEEP is effective, relatively low cost, and widely used for cervical intraepithelial neoplasia. Yet treatment does not end at the procedure room. Residual or recurrent disease may occur months or years later, especially when high-risk human papillomavirus persists, excision margins are involved, or post-treatment surveillance is incomplete.
This article reviews recurrence of preinvasive cervical lesions after LEEP at KCMC, with attention to clinical risk factors, demographic patterns, and follow-up care. The discussion is informational and intended for medical readers, not as a substitute for local clinical guidelines or specialist judgement.
Why recurrence after LEEP matters at KCMC
Cervical cancer remains one of the leading causes of cancer morbidity and mortality among women in sub-Saharan Africa. Globally, recent estimates place the annual burden at about 660,000 new cervical cancer cases and 350,000 deaths, with most deaths occurring in low- and middle-income countries. Eastern Africa carries one of the highest regional burdens.
Tanzania has expanded screening and treatment services through visual inspection with acetic acid, HPV testing in selected programmes, cryotherapy, thermal ablation, and excisional treatment. KCMC plays a major role as a tertiary and referral centre, often managing patients with high-grade lesions, large transformation zones, uncertain eligibility for ablative treatment, or suspected invasive disease.
LEEP offers several advantages in this setting:
It removes the transformation zone and allows histopathological assessment.
It can treat high-grade squamous intraepithelial lesions in a single visit when systems allow.
It helps exclude microinvasive carcinoma when colposcopy or biopsy raises concern.
The main challenge is that excision lowers risk but does not eliminate it. Recurrence places patients back into a high-risk pathway and may strain clinic capacity. It also reflects broader health-system performance, including counselling, documentation, recall, pathology reporting, and access to transport.
What counts as recurrence after LEEP
Clinical studies define recurrence in different ways, which makes direct comparison difficult. In practice, recurrence after LEEP usually refers to detection of cervical intraepithelial neoplasia grade 2 or worse after initial treatment and a disease-free interval. Some studies include persistent disease, which appears at the first post-treatment assessment, while others separate persistence from true recurrence.
A useful distinction is:
Term | Practical meaning | Common timing |
Residual disease | Lesion likely not fully removed at treatment | Detected at first follow-up, often within 6 months |
Recurrent disease | Lesion returns after an initial negative assessment | Usually detected after 6 to 12 months or later |
Persistent HPV infection | High-risk HPV remains detectable after treatment | Can precede cytological or histological recurrence |
For KCMC, a standardised definition is essential. Without it, recurrence rates may appear high or low because of classification choices rather than true clinical performance. A patient with CIN2+ at 6 months after positive excision margins may represent residual disease. A patient with negative follow-up at 6 months and CIN3 at 24 months fits better under recurrence.
What recent research says about recurrence rates
International evidence shows that LEEP is highly effective, but recurrence remains clinically important. Across studies, rates of recurrent CIN2+ after excisional treatment often fall in the broad range of 5% to 15%, with higher rates in cohorts enriched for HIV infection, positive margins, poor follow-up, or persistent high-risk HPV.
Persistent high-risk HPV after treatment is one of the strongest predictors of recurrent CIN2+, often outperforming margin status alone.
Meta-analyses and guideline reviews consistently show these patterns:
Negative margins plus HPV clearance are associated with very low recurrence risk.
Positive excision margins increase recurrence risk several-fold, although many patients with positive margins do not recur.
Persistent HPV16 or HPV18 carries higher risk than many other high-risk genotypes.
Immunosuppression, especially HIV infection with low CD4 counts or unsuppressed viral load, increases the likelihood of persistence and recurrence.
Long-term risk remains elevated compared with the general screened population, even after apparently successful treatment.
Recent post-treatment surveillance research has also moved away from cytology-only follow-up. HPV-based testing is more sensitive for detecting women at risk after excision. The challenge in many lower-resource settings is availability, cost, laboratory capacity, and linkage of results to care.
Patient factors that may influence recurrence at KCMC
Recurrence patterns at a referral centre like KCMC are shaped by more than lesion biology. Patient demographics, reproductive history, HIV status, and access to follow-up all affect observed outcomes.
Age and menopausal status
Age alters both risk and detectability. Younger patients may clear HPV more effectively, but they can also have ongoing exposure to high-risk HPV. Older patients may have transformation zones that recede into the endocervical canal, making colposcopy and complete excision more difficult.
In postmenopausal patients, type 3 transformation zones may increase the risk of incomplete excision or missed endocervical disease. This can make follow-up cytology or HPV testing especially important after LEEP.
HIV status and immune function
HIV is one of the most relevant factors in the Tanzanian context. Women living with HIV have higher rates of HPV persistence, multiple HPV genotype infection, and recurrent cervical dysplasia after treatment. Antiretroviral therapy reduces risk but does not fully normalise it.
For analysis at KCMC, HIV-related variables should include:
HIV status at treatment
CD4 count where available
Antiretroviral therapy status
Viral suppression where available
History of prior cervical treatment
A recurrence audit that records HIV status but not immune or treatment markers may miss key differences within the HIV-positive group.
Parity, contraceptive history, and smoking
High parity has been associated with cervical cancer risk in epidemiological studies, likely through hormonal, immunological, and cervical trauma pathways. Its independent role in post-LEEP recurrence is less consistent, but it may correlate with age, screening history, and healthcare access.
Smoking is a well-established cofactor for cervical neoplasia in many populations. In settings where smoking prevalence among women is low, its contribution may be limited, but it should still be documented. Long-term hormonal contraceptive use has been linked with cervical cancer risk in some studies, though its role in recurrence after adequate treatment remains less clear.
Clinical and pathological factors that predict recurrence
The strongest recurrence predictors are usually found in the clinical and pathology record. High-quality documentation at KCMC can turn routine care into a strong evidence base.
Lesion grade before and after treatment
Women treated for CIN3 generally carry higher recurrence risk than those treated for CIN2. If invasive cancer is missed at baseline, apparent “recurrence” may actually represent underdiagnosed disease. This makes careful pre-treatment evaluation critical, especially when lesions are extensive, suspicious, or discordant with cytology.
Excision margin status
Margin status is one of the most practical pathology markers. Positive endocervical margins are often more concerning than ectocervical margins because residual disease may remain higher in the canal.
Still, margin status should not be used in isolation. Some women with positive margins clear residual disease, while some with negative margins recur due to persistent HPV or new infection. The best risk assessment combines margin status, HPV testing, cytology, and colposcopic findings.
Glandular involvement and lesion size
Endocervical gland involvement may signal a more extensive lesion. Large lesions and lesions extending into the canal can be harder to remove completely with a single pass. Fragmented specimens may also reduce the reliability of margin interpretation.
LEEP reports should ideally capture:
CIN grade
Margin status and margin location
Glandular involvement
Specimen fragmentation
Suspicion of microinvasion
Transformation zone type where documented
Treatment technique
Recurrence can also reflect technical factors. A shallow excision may preserve cervical tissue but leave disease behind. An overly aggressive excision may increase obstetric risk without clear benefit. The goal is an adequate specimen tailored to lesion size, transformation zone type, and reproductive considerations.
Follow-up care is the decisive variable
In many recurrence studies from sub-Saharan Africa, the most difficult issue is not the procedure. It is retaining patients in post-treatment surveillance.
Follow-up loss can distort recurrence estimates in two directions. If only symptomatic or high-risk patients return, recurrence may appear higher than it truly is. If many patients with recurrence never return, the measured rate may appear falsely low.
A strong post-LEEP follow-up pathway should include:
Clear counselling before discharge
Written follow-up date and reason for review
Phone-based reminders where feasible
HPV testing when available
Cytology, VIA, or colposcopy according to local protocol
Fast referral for abnormal post-treatment findings
Documentation of patients who transfer care or cannot be reached
WHO’s cervical cancer elimination strategy sets targets of 90% HPV vaccination, 70% screening coverage, and 90% treatment access for eligible women. Post-treatment surveillance is not always highlighted in the same way, but it is essential to the success of all three goals. Treating a lesion without confirming cure leaves a gap in the prevention pathway.
How KCMC can interpret recurrence data
A local recurrence analysis should avoid treating all post-LEEP patients as a single risk group. Stratification gives a clearer picture of what drives recurrence and where care can improve.
Useful analytic categories include:
Factor group | Variables to review | Why it matters |
Demographic profile | Age, residence, parity, referral source | Identifies access barriers and high-risk groups |
HIV-related status | HIV status, ART use, CD4 count, viral suppression | Captures immunological risk |
Lesion characteristics | CIN grade, transformation zone type, gland involvement | Reflects baseline disease burden |
Procedure quality | Margin status, specimen size, fragmentation | Estimates completeness of excision |
Follow-up care | Time to first visit, test used, missed appointments | Determines detection and prevention of progression |
For KCMC, residence and referral distance may be particularly relevant. Patients who travel from rural districts may face transport costs, work constraints, and limited recall systems. A patient may fully intend to return but fail to do so because the follow-up model does not match her circumstances.
The analysis should also separate “no recurrence” from “no documented follow-up”. These are not equivalent. A high proportion of missing follow-up data weakens any recurrence estimate.
Clinical implications for reducing recurrence
Reducing recurrence after LEEP requires a combined clinical and public health approach.
Improve pre-treatment assessment
Careful patient selection matters. Large lesions, suspected glandular disease, discordant cytology and biopsy, or suspicion of invasion should prompt senior review. Where available, colposcopy-directed biopsy and endocervical sampling can improve diagnostic accuracy.
Strengthen pathology feedback
LEEP is only as useful as the information returned from histopathology. Fast reporting of margin status and grade allows clinicians to triage patients into appropriate follow-up intensity. Standardised pathology templates can improve completeness.
Use risk-based follow-up
Women with negative margins, HPV clearance, and reliable follow-up access may need less intensive surveillance than women with positive margins, HIV infection, or persistent high-risk HPV. Risk-based follow-up can help clinics focus limited resources where they prevent the most harm.
Integrate HIV and cervical care
For women living with HIV, cervical surveillance should connect with ART clinics. Shared appointment systems, viral load monitoring, and counselling can reduce missed visits and improve immune recovery. This integrated model is especially relevant in high HIV-burden regions.
Track outcomes beyond the first visit
Six-month follow-up is valuable, but it is not enough. Recurrence can occur later. A KCMC registry that tracks treatment date, pathology, follow-up tests, and outcomes over multiple years would provide stronger evidence than isolated clinic notes.
Research priorities for KCMC and similar centres
A high-quality local study on recurrence after LEEP should answer several practical questions:
What proportion of treated patients return for first follow-up within the recommended interval?
What is the rate of histologically confirmed CIN2+ after treatment?
How does recurrence differ by HIV status and ART markers?
How strongly do positive margins predict recurrence in this population?
Does HPV-based surveillance detect risk earlier than VIA or cytology?
Which patients are most likely to be lost to follow-up?
The most useful design would be a retrospective cohort strengthened by prospective follow-up. A minimum dataset should include demographics, HIV-related variables, reproductive history, screening result, biopsy diagnosis, LEEP pathology, margin status, follow-up method, follow-up timing, and final outcome.
Because recurrence estimates depend heavily on follow-up completeness, the study should report both recurrence among those followed and follow-up retention among all treated patients. That distinction makes the findings clinically honest and policy-relevant.
Takeaway
LEEP remains a central tool for preventing cervical cancer at Kilimanjaro Christian Medical Centre, but recurrence after treatment is shaped by more than excision technique. Persistent high-risk HPV, positive margins, HIV-related immunosuppression, high-grade disease, endocervical involvement, and incomplete follow-up all influence outcomes.
The most practical path forward is clear: treat adequately, report pathology consistently, stratify patients by risk, and build follow-up systems that patients can realistically complete. For KCMC and similar referral centres, recurrence data should be used not only to measure treatment success, but also to strengthen the full cervical cancer prevention pathway.
Comments